Fannie Mae, Freddie Mac shares tumble after conservatorship comments
NEW BRUNSWICK, N.J. - Johnson & Johnson (NYSE: JNJ) announced Tuesday that Daniel Pinto, President of JPMorgan Chase, has been elected to its Board of Directors.
Pinto, who has more than three decades of financial expertise, currently serves as President at JPMorgan Chase and is a member of the company’s Operating Committee. He began his career at Manufacturers Hanover in 1983 in Buenos Aires and has held numerous leadership positions throughout his tenure at JPMorgan Chase and its predecessor companies.
"He is an exceptional leader with deep financial expertise and understanding of global capital markets," said Joaquin Duato, Chairman and Chief Executive Officer of Johnson & Johnson, in a press release statement.
In January 2025, Pinto announced plans to retire from JPMorgan Chase at the end of 2026. He will retain his role as President until June 30, 2025, after which he will serve as Vice Chairman through 2026.
Pinto holds a bachelor’s degree in Public Accounting and Business Administration from Universidad Nacional de Lomas de Zamora in Buenos Aires and serves on the Board of Directors of the Institute of International Finance.
Johnson & Johnson, a global healthcare company, operates in Innovative Medicine and MedTech sectors. The company focuses on developing treatments for complex diseases and healthcare solutions.
In other recent news, Johnson & Johnson has unveiled new data from its CARTITUDE-1 study, showing that 33% of patients with relapsed or refractory multiple myeloma treated with CARVYKTI experienced progression-free survival for five years or more. This data, presented at the American Society of Clinical Oncology Annual Meeting, underscores the potential of CARVYKTI as a long-lasting treatment for multiple myeloma. Additionally, initial results from a Phase 1 trial of Johnson & Johnson’s investigational trispecific antibody, JNJ-5322, revealed an overall response rate of 86.1% among patients. Meanwhile, Leerink Partners has downgraded Johnson & Johnson’s stock from Outperform to Market Perform due to concerns about potential price controls on Darzalex Faspro. The firm adjusted its price target to $153, citing revised expectations for the drug’s profit contributions. In the field of dermatology, Johnson & Johnson reported promising results from its Phase 3 study on icotrokinra for plaque psoriasis, with 57% of participants achieving clear or almost clear skin. Furthermore, the company shared findings from the QUASAR study, indicating sustained remission in ulcerative colitis patients treated with TREMFYA at 92 weeks. These developments highlight Johnson & Johnson’s ongoing efforts in advancing treatment options across various medical conditions.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.